STOCK TITAN

Director Christopher Gibson receives options and RSUs at Pacific Biosciences (PACB)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Christopher Gibson reported equity awards consisting of stock options and restricted stock units tied to his recent Board appointment. He received stock options covering 77,842 shares of Common Stock at an exercise price of $1.52 per share, expiring on April 8, 2036. One-third of these option shares will vest on March 3, 2027, with the remainder vesting in equal monthly installments over the following 24 months, contingent on continued Board service. He also acquired 57,473 shares of Common Stock represented by restricted stock units that vest in three equal annual installments on March 3 of 2027, 2028, and 2029, subject to his continued service as a director. Following these grants, he directly holds 111,386 shares of Common Stock.

Positive

  • None.

Negative

  • None.
Insider Gibson Christopher
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 77,842 $0.00 --
Grant/Award Common Stock 57,473 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 77,842 shares (Direct); Common Stock — 111,386 shares (Direct)
Footnotes (1)
  1. Mr. Gibson was elected to the Board of Directors on March 3, 2026. Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on March 3rd of each of 2027, 2028, and 2029, provided such Reporting Person continues to serve as a director through the applicable vesting dates. One-third of the shares subject to the option will vest on March 3, 2027, which is the one year anniversary of Mr. Gibson joining the Board, and the remainder will vest in equal monthly installments thereafter for 24 months on the same date of the month as his initial start date, provided he continues to serve as a director through each vesting date.
Stock options granted 77,842 shares Stock Option grant on April 8, 2026
Option exercise price $1.52 per share Exercise price for 77,842 options
Option expiration April 8, 2036 Expiration date of granted options
RSU shares granted 57,473 shares Common Stock represented by RSUs granted April 8, 2026
Common shares after grants 111,386 shares Total direct Common Stock holdings following transactions
Initial option vesting date March 3, 2027 One-third of option shares vest on this date
RSU vesting period 2027-2029 Annual RSU vesting on March 3 of each year
Restricted Stock Unit ("RSU") financial
"Each share is represented by a Restricted Stock Unit ("RSU")."
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
vest in equal annual installments financial
"The RSUs will vest in equal annual installments on March 3rd"
Board of Directors financial
"Mr. Gibson was elected to the Board of Directors on March 3, 2026."
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
exercise price financial
"conversion_or_exercise_price": "1.5200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gibson Christopher

(Last)(First)(Middle)
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
1305 O'BRIEN DRIVE

(Street)
MENLO PARK CALIFORNIA 94025

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. [ PACB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/08/2026A57,473(1)A$0111,386D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.5204/08/2026A77,84203/03/2027(2)04/08/2036Common Stock77,842$077,842D
Explanation of Responses:
1. Mr. Gibson was elected to the Board of Directors on March 3, 2026. Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on March 3rd of each of 2027, 2028, and 2029, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
2. One-third of the shares subject to the option will vest on March 3, 2027, which is the one year anniversary of Mr. Gibson joining the Board, and the remainder will vest in equal monthly installments thereafter for 24 months on the same date of the month as his initial start date, provided he continues to serve as a director through each vesting date.
Remarks:
/s/ Brett Atkins, Attorney-in-fact04/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Christopher Gibson acquire in this PACB Form 4 filing?

Christopher Gibson received stock options and restricted stock units (RSUs). He was granted options for 77,842 shares at a $1.52 exercise price and 57,473 RSU shares, all tied to his role on Pacific Biosciences’ Board and subject to future vesting conditions.

How many PACB stock options were granted to director Christopher Gibson?

Christopher Gibson was granted options on 77,842 PACB shares. These options have a $1.52 per share exercise price and expire on April 8, 2036. Vesting begins March 3, 2027, with one-third vesting then and the rest monthly over the next 24 months.

What are the vesting terms of Christopher Gibson’s PACB restricted stock units?

The 57,473 RSU shares vest in three equal annual installments. They vest on March 3 of 2027, 2028, and 2029, provided Gibson continues to serve as a director through each applicable vesting date, aligning his compensation with ongoing Board service.

What is Christopher Gibson’s PACB common stock holding after these grants?

After the reported transactions, Gibson directly holds 111,386 PACB common shares. This total reflects the addition of 57,473 granted shares represented by RSUs, which will vest over time, in addition to his prior holdings as disclosed in the filing.

When do Christopher Gibson’s newly granted PACB stock options vest?

Gibson’s PACB options start vesting on March 3, 2027. One-third of the 77,842 option shares vest then, marking his one-year Board anniversary. The remaining two-thirds vest in equal monthly installments over the following 24 months, contingent on continued Board service.

Why were these PACB equity awards granted to Christopher Gibson?

The equity awards relate to Gibson’s election to the Board of Directors. He joined the Board on March 3, 2026, and received options and RSUs that vest over several years, designed to align his compensation with long-term service and company performance.